Skip to content

Pregnancy outcome among HIV-infected women on different antiretroviral therapies in Ethiopia: a cohort study

Research output: Contribution to journalArticle

  • Yohannes Ejigu
  • Jeanette H. Magnus
  • Johanne Sundby
  • Maria C. Magnus
Original languageEnglish
Article numbere027344
Number of pages9
JournalBMJ Open
DateAccepted/In press - 21 Jun 2019
DatePublished (current) - 5 Aug 2019


OBJECTIVE: The objective of the study was to compare pregnancy outcomes according to maternal antiretroviral treatment (ART) regimens.

DESIGN: A retrospective cohort study.

PARTICIPANTS AND SETTINGS: Clinical data was extracted from ART exposed pregnancies of HIV-infected Ethiopian women attending antenatal care follow-up in public health facilities in Addis Ababa between February 2010 and October 2016.

OUTCOMES: The primary outcomes evaluated were preterm birth, low birth weight and small-for-gestational-age.

RESULTS: A total 1663 of pregnancies exposed to ART were included in the analyses. Of these pregnancies, 17% resulted in a preterm birth, 19% in low birth weight and 32% in a small-for-gestational-age baby. Compared with highly active antiretroviral therapy (HAART) initiated during pregnancy, zidovudine monotherapy was less likely to result in preterm birth (adjusted OR 0.35, 95% CI 0.19 to 0.64) and low birth weight (adjusted OR 0.48, 95% CI 0.24 to 0.94). We observed no differential risk of preterm birth, low birth weight and small-for-gestational-age, when comparing women who initiated HAART during pregnancy to women who initiated HAART before conception. The risk for preterm birth was higher in pregnancies exposed to nevirapine-based HAART (adjusted OR 1.44, 95% CI 1.06 to 1.96) compared with pregnancies exposed to efavirenz-based HAART. Comparing nevirapine-based HAART with efavirenz-based HAART indicated no strong evidence of increased risk of low birth weight or small-for-gestational-age.

CONCLUSIONS: We observed a higher risk of preterm birth among women who initiated HAART during pregnancy compared with zidovudine monotherapy. Pregnancies exposed to nevirapine-based HAART also had a greater risk of preterm births compared with efavirenz-based HAART.

    Research areas

  • antiretroviral therapy, HIV, low birth weight, preterm birth, small-for-gestational-age

Download statistics

No data available



  • Full-text PDF (final published version)

    Rights statement: This is the final published version of the article (version of record). It first appeared online via BMJ Publishing Group at . Please refer to any applicable terms of use of the publisher.

    Final published version, 338 KB, PDF document

    Licence: CC BY-NC


View research connections

Related faculties, schools or groups